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Abstract 
 
European guidelines recommend that patients with hypertension are assessed for asymptomatic 
organ damage and secondary causes. We propose that a single magnetic resonance imaging (MRI) 
scan can provide comprehensive first-line imaging of patients assessed via a specialist hypertension 
clinic. 
200 patients (56% male, aged 51±15 years, office BP 168±30 / 96±16 mmHg) underwent MRI of the 
heart, kidneys, renal arteries, adrenals and aorta. Comparisons were made with other imaging 
modalities where available. 61% had left ventricular hypertrophy (LVH), 14% reduced ejection 
fraction and 15 patients had myocardial infarcts. Echocardiography over-diagnosed LVH in 15% and 
missed LVH in 14%. Secondary causes were identified in 14.5% of patients: 12 adrenal masses, 10 
renal artery stenoses, 7 thyroid abnormalities, 1 aortic coarctation, 1 enlarged pituitary gland, 1 
polycystic kidney disease, 1 renal coloboma syndrome.  
Our comprehensive MRI protocol is an effective method of screening for asymptomatic organ 
damage and secondary causes of hypertension.  
  
Introduction 
 
Hypertension is a global health problem; at least a quarter of the adult population has high blood 
pressure (BP) and the world-wide prevalence is predicted to rise to 1.56 billion by 2025(1). The 2013 
European Society of Hypertension / European Society of Cardiology guidelines for the management 
of arterial hypertension recommend that all patients with high BP are investigated for asymptomatic 
target organ damage to enable evaluation of their cardiovascular risk, and thus guide the initiation 
of appropriate treatment(2). Initial assessment with a 12-lead electrocardiogram (ECG) and basic 
biochemical tests is advised as standard for all patients, with guidance that additional testing should 
be performed if indicated by history or examination findings(2). Investigation for secondary causes 
of hypertension is recommended where there is clinical suspicion(2). In the United Kingdom, the 
2011 National Institute for Health and Care Excellence guideline on the diagnosis and management 
of hypertension in adults also recommends additional investigation in patients at higher risk of 
secondary hypertension, specifically including those with young onset hypertension (<40 years old), 
treatment resistant hypertension, rapidly worsening or accelerated hypertension, or in those with 
history or examination findings that might indicate a secondary cause(3). 
 
In this study we aimed to establish the utility of magnetic resonance imaging (MRI) as a screening 
tool in hypertension in patients assessed via a specialist hypertension clinic. The European guidelines 
acknowledge the value of cardiac MRI, but recommend echocardiography and peripheral 
arterial/abdominal ultrasound as first line imaging modalities (2). However, as MRI becomes 
increasingly available, it is likely to prove a useful tool in the assessment of patients. For example, 
cardiac MRI (CMR) is widely regarded as the gold standard non-invasive imaging modality for the 
clinical assessment of left ventricular mass (LVM) and left ventricular hypertrophy (LVH)(4), and 
additionally, MRI techniques can be used to image the vasculature (including the renal arteries), 
renal parenchyma and adrenal glands with high accuracy(5, 6). MRI could improve diagnostic 
efficiency in these patients as it is a highly sensitive imaging modality and would avoid the need for 
multiple appointments for echocardiography, renal ultrasound and, potentially, vascular computed 
tomography (CT) angiography.  
 
We propose that a single MRI scan could provide all of the routine imaging required for the 
evaluation of both target organ damage and the identification of potential secondary causes in 
patients in the context of a tertiary hypertension service. 
 
  
Methods 
 
Study population 
This was a retrospective analysis of 200 consecutive patients assessed with a hypertension protocol 
MRI scan, from a prospectively gathered clinical database of patients investigated at a tertiary 
hypertension clinic (Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust). 
Eligible study participants were those referred for MRI as part of their standard clinical hypertension 
work-up between November 2010 and July 2015, and includes patients with young onset 
hypertension (yHTN, onset <40yrs), drug resistant hypertension (rHTN, BP >140/90 mmHg despite ≥ 
3 anti-hypertensive medications), uncontrolled hypertension (ucHTN, BP >140/90 mmHg on <3 anti-
hypertensives), and other difficult to treat hypertension (e.g. accelerated hypertension, highly labile 
hypertension or hypertension with disproportionate target organ damage).  
 
Baseline demographics and clinical characteristics were recorded. Patient height and weight were 
measured with calculation of body mass index (BMI). A BMI ≥ 30kg/m2 was defined as obesity(7). 
Office systolic (SBP) and diastolic blood pressures (DBP) were measured in the seated position using 
a standard oscillometric device and appropriately sized cuff, taking the mean of at least two repeat 
readings, where available.  
 
To assess the reliability of our MRI findings, results were compared with the clinical reports from 
previous echocardiographic, renal ultrasound or renal CT angiographic studies performed as part of 
each participant’s hypertension assessment. Likewise, results from CT scans performed as part of 
any additional evaluation for patients with positive findings on MRI were also reviewed. 
 
The local research ethics committee confirmed that the study conformed to the governance 
arrangements for research ethics committees (REC). The study was conducted with the patients’ 
written consent. The study was performed in accordance with the declaration of Helsinki. 
 
 
MRI protocol 
Images were acquired from the level of the Circle of Willis to the level of the femoral heads.  
 
CMR was performed at 1.5 Tesla (Avanto, Siemens, Erlangen, Germany). Steady-state free 
precession short-axis whole LV cines (8 mm slice thickness, no slice gap, temporal resolution 38.1 
ms, echo time 1.07 ms, representative field-of-view (FOV) in-plane pixel size 1.5 × 0.8 mm) were 
used for the estimation of LV mass and volumes. Myocardial replacement fibrosis was assessed by 
late gadolinium enhancement (LGE)(8). An inversion-recovery fast gradient-echo sequence was 
performed 10–15 min after intravenous administration of 0.1 mmol/kg gadobutrol (Gadovist, Bayer 
Pharma AG, Germany), in two phase-encoding directions where there was potential artefact. 
Tailored inversion times were used in each patient to null normal reference myocardium.  
 
Renovascular assessment consisted of Time-resolved angiography With Interleaved Stochastic 
Trajectories (TWIST) contrast enhanced magnetic resonance angiography (MRA), which creates 
multi-phase, multi-planar images of the thoracic and abdominal vasculature; angiography was 
analysed using multiplanar reformatting post-processing software (cmr42; Circle Cardiovascular 
Imaging Inc., Calgary, AB, Canada). Axial T1-weighted images through the abdomen and pelvis with 
5mm slice thickness were also performed. 
 
CMR analysis 
The assessment of left ventricular volumes and LVM were performed as described previously(9). 
Briefly, endocardial contours were defined at end-diastole and end-systole on the LV short-axis stack 
using blood pool/endocardial border threshold detection software (cmr42; Circle Cardiovascular 
Imaging Inc., Calgary, AB, Canada), which has been previously validated(10). Epicardial contours 
were defined manually at end diastole. The LVM was estimated by multiplying the total myocardial 
volume, including papillary muscles and LV trabeculations (equivalent to LV dry weight), by 1.05 
g/ml, which is the specific gravity of myocardium, as described previously(9). The LVM was indexed 
to body surface area, calculated using the Mosteller formula. Ejection fraction was calculated from 
the end-diastolic and end-systolic endocardial volumes, and long axis function was assessed using 
mitral and tricuspid annular plane systolic excursion. 
 
LVH was defined as indexed LVM >95th percentile of established CMR reference ranges indexed to 
body surface area (men: <35 years, >87 g/m2; ≥35 years, >78 g/m2 and women: <35 years, >71 g/m2; 
≥35 years, >70g/m2)(11). LV remodelling was defined as a ventricle with normal indexed LVM but 
elevated LV mass/volume ratio (M/V)(12). An increased M/V was defined as >95th gender-specific 
percentile (men: >1.12 g/ml and women:>1.14 g/ml) from healthy volunteers, as described 
previously(12). The presence of LGE was quantified by visual analysis. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism (La Jolla, CA, USA). All data presented as 
mean ± standard deviation The chi-squared test was used to compare categorical data. A Kruskal-
Wallis test was used to compare non-parametric data, with Dunn’s multiple comparison test 
between groups.   Significance was taken as p<0.05. 
 
Results 
Demographic data 
Data from two hundred consecutive patients from our specialist hypertension clinic who underwent 
MRI as the imaging component of their assessment for target organ damage and potential 
secondary causes of hypertension are presented. 38% of patients had drug resistant hypertension, 
32% had young onset hypertension, 18% had uncontrolled hypertension, and 12% had other difficult 
to treat hypertension. Patient demographic data is shown in Table 1. There were no adverse events 
as a result of the MRI scans; however one scan was abandoned due to claustrophobia. All patients 
except one (renal coloboma syndrome) had an eGFR of >30 ml/min/1.73m2. 
 
Target organ damage detected by MRI 
Overall, 79% (157/200) of patients had evidence of target organ damage. The proportion of patients 
with target organ damage differed between the four hypertension subgroups (see Table 2, 
p<0.0001); 92% (70/76) of patients with rHTN, 59% (38/64) with yHTN, 89% (31/35) with ucHTN and 
72% (18/25) with other HTN.  
 
In this study cohort, 61% (122/200) of patients had LVH and 7% (13/200) had left ventricular 
remodeling without hypertrophy. An example of left ventricular hypertrophy is shown in Figure 1A. 
Late gadolinium enhancement demonstrated left ventricular replacement fibrosis in 15% (30/200) of 
patients; the 15 patients with a non-infarction pattern of LGE all had mild patchy intramyocardial 
enhancement. Based on the nature of their LVH, characteristic basal mid-wall fibrosis and others 
markers, four patients were reclassified with probable hypertrophic cardiomyopathy (see example in 
Figure 1B)(13, 14). From a functional perspective, 14% (27/200) of patients had reduced ejection 
fraction and 42% (84/200) had impaired long-axis function. There was a difference in LVM between 
hypertension groups (see Table 1, p<0.01) with a significant difference between those with rHTN and 
yHTN on subgroup analysis (p<0.05). Viewed as the proportion of patients in each hypertension 
subgroup with LVH, there was also a significant difference between groups (see Table 2, p<0.0001); 
LVH in 74% (56/76) of those with rHTN, 38% (24/64) of those with yHTN, 74% (26/35) with ucHTN 
and 64% (16/25) with other HTN.  
 
We identified 15 (7.5%) individuals with evidence of a previous myocardial infarction, seen as sub-
endocardial scarring in a coronary artery distribution on late gadolinium enhancement (see Figure 
1C&D); in 5 of these patients this was a novel diagnosis. 44 patients (22%) had an ectatic aorta 
(surgical intervention not indicated) and  six patients had evidence of significant pre-existing cerebral 
or peripheral vascular disease and were on secondary prevention medication.  
 
Secondary causes of hypertension identified by MRI scanning 
 29 patients (14.5%) had potential secondary causes of hypertension identified on MRI. There was a 
difference in the proportion of patients with a potential secondary cause on imaging between the 
hypertension subgroups (see Table 2, p=0.04); secondary causes were identified in 17% (13/76) of 
those with rHTN, 6% (4/64) of those with yHTN, 23% (8/35) of those with ucHTN and 28% (7/25) 
with other hypertension. In the full cohort, we identified 12 patients with adrenal 
masses/hyperplasia (including two reported as phaeochromocytomas), 10 with renal artery stenoses 
(RAS), 6 with renal abnormalities potentially causing secondary hypertension (4 renal atrophy, 1 
polycystic kidney disease, one renal coloboma syndrome), 7 with thyroid abnormalities, one 
individual with aortic coarctation, and one with an enlarged pituitary gland (some patients had more 
than one pathology identified). 27% of patients had ≥1 accessory renal artery. See Table 3 for details, 
examples are shown in Figure 2.  It should also be noted that 47% of the study patients were obese, 
however, when comparing those with and without obesity, a similar proportion of patients had 
another potential secondary cause of hypertension identified on MRI in this cohort (13/93 (14%) vs 
26/107 (15%), p=ns).  
 
MRI versus other imaging modalities 
MRI results were compared with conventional echocardiographic, renal ultrasound or CT scans 
performed as part of a participant’s hypertension assessment, where available. In this cohort, 84 
patients had had previous echocardiograms, 81 had had renal ultrasound, and 11 patients had CT 
imaging (adrenal protocol CT or renal CT angiography) either prior to their MRI scan or as part of 
more focused investigation of their MRI findings. 
 
When compared to CMR, echocardiography over-diagnosed LVH in 15% (false positive) and missed 
LVH in 14% (false negative). Echocardiography had a sensitivity of 79% and specificity of 64% for the 
detection of LVH in this dataset (see Supplementary Table 1 for predictive values). Simple renal 
ultrasound assessment failed to detect four cases of RAS. One patient who had ‘normal’ adrenal 
glands reported on MRI had a 6mm adenoma identified on subsequent focused adrenal CT imaging, 
which was performed due to positive biochemistry indicating Conn’s syndrome; this was 
retrospectively not visible on the initial MRI. In another case, an adrenal mass was reported as a 
likely phaeochromocytomas on MRI, but was felt to be benign following endocrine testing and a 
dedicated adrenal CT (see Table 3). Following initial investigation with MRI, further imaging was 
recommended in 24/200 patients; this included focused CT to further characterize renal artery 
stenoses and adrenal masses, ultrasound of thyroid abnormalities (all benign except an MEN2a 
case), or imaging of other incidental findings. 
 
Discussion 
We have shown that MRI is a safe and effective imaging strategy for evaluating target organ damage 
and screening for secondary causes in patients assessed within the context of a specialist 
hypertension clinic. MRI has the significant benefit of being able to image multiple systems in one 
session, and is a low risk investigation that does not involve ionizing radiation; this is particularly 
relevant when investigating patients with young onset disease who may go on to have repeated 
imaging during their lifetimes. The high prevalence of pathology seen in this study justifies the use of 
more advanced imaging techniques in higher risk/more complex patients with hypertension as 
recommended by European guidelines(2).  
Asymptomatic target organ damage was identified in over three quarters of our study population, 
and most notably, LVH was demonstrated in 61% of the patients. The prevalence of target organ 
damage and LVH differed between the subgroups of hypertensive patients in this study. Fewer 
patients with young onset hypertension had LVH, and whilst this may reflect the fact that these 
patients have been exposed to high BP for a shorter period of time, the development of different 
hypertensive heart disease phenotypes is likely to be multifactorial (15). The level of left ventricular 
hypertrophy across the full study cohort is higher than the 36-41% prevalence seen in the general 
hypertensive population(16), however, we present data for those requiring assessment in a tertiary 
clinic. Target organ damage is highly prevalent in established HTN (echocardiographic LVH seen in 
55-75% of patients with rHTN (17)), and healthcare professionals should have a low threshold to 
request further imaging in these individuals, particularly if this will alter management due to 
increased cardiovascular risk. 
In this cohort there was also a relatively high (14.5%) prevalence of potential secondary causes of 
hypertension compared with the 5-10% rate of secondary hypertension reported amongst general 
hypertensive populations (18-20). Once parallel biochemical testing is taken into account, the 
prevalence of secondary hypertension seen in this study cohort may be more consistent with rates 
of secondary hypertension of 20-31% seen in patients with more severe or treatment resistant 
hypertension(21, 22). 
There was a significant difference between the prevalence of secondary causes between the 
subgroups of hypertensive patients in this study. The highest prevalence of secondary causes was in 
the ‘other’ hypertension group; this reflects the nature of the patients in this group, some of whom 
were referred to the clinic for additional assessment of known secondary hypertension. However, it 
is interesting that fewer of those with yHTN had possible evidence of secondary hypertension 
compared with the other groups. It might have been expected that yHTN patients would be more 
likely to have a vascular or endocrine condition as a driver for the early onset of their disease. 
Conversely, 23% of those with ucHTN had a potential secondary cause of hypertension on MRI, even 
though their persistently high BP could be attributed to insufficient pharmacotherapy and these 
patients would not necessarily be considered to be at higher risk of secondary hypertension.  
MRI is widely regarded as the gold standard non-invasive technique for assessing left ventricular 
volumes and mass(4), and also provides information about systolic and diastolic cardiac function(9). 
Whilst ECG is widely available as a screening tool, it has a relatively low sensitivity for LVH, 
particularly in those with obesity(23, 24). MRI is also superior to echocardiography for the 
assessment of LVM(25-27) (see Supplementary Table 1 for data on the accuracy of diagnosis of LVH 
using ECG or echocardiography versus CMR). The European Guidelines do not place much emphasis 
on myocardial dysfunction as a marker of target organ damage(2), however in this study 14% of 
patients had reduced ejection fraction and 42% had impaired long-axis function; ejection fraction 
was generally preserved in our cohort, but using this parameter alone may miss significant cardiac 
systolic dysfunction in the presence of LVH(28).  
MRI can also be used to characterize any change in the geometry of the left ventricle. Patients with 
normal range LVM, but concentric left ventricular remodeling are at increased cardiovascular risk 
compared with those with normal left ventricular mass and structure(29). The other additional 
advantage of MRI is the ability to evaluate replacement fibrosis using late gadolinium 
enhancement(30); in this study 5/15 myocardial infarctions seen on MRI were unexpected diagnoses 
and resulted in initiation of secondary prevention medication. Accurate evaluation of LVM, 
morphology and fibrosis also helps to differentiate between hypertensive heart disease and 
hypertrophic cardiomyopathy, which makes MRI an important tool for assessing patients with 
significant LVH and concurrent hypertension(6, 14, 31, 32). The use of gadolinium as an MRI contrast 
agent carries a risk of nephrogenic systemic fibrosis (NSF), quantified as an incidence of 0.02% in one 
retrospective, multicentre study of 83121 patients(33). Those with an estimated glomerular filtration 
rate of <30 ml/min/1.73m2 are at highest risk of NSF (34). Novel techniques MRI techniques provide 
even more additional information; T1 mapping can quantify diffuse interstitial fibrosis (35, 36) and 
wave intensity analysis can be used to assess vascular stiffness(37). Table 4 summarises the 
comparison between different investigation modalities for the evaluation of LVH. 
MRI is also a useful diagnostic tool for identifying potential secondary causes of hypertension (31). 
Renal artery stenosis was identified in 5% of our study population, but has been reported in as many 
as 24% of patients with resistant hypertension (38). European guidelines recommend duplex 
ultrasound as the first line investigation for RAS(2). This technique is non-invasive, but ultrasound 
can be limited by body habitus,does not penetrate air from bowel gas, and is not the ‘gold-standard’ 
examination for excluding RAS. Duplex ultrasound is also highly operator dependent with a 
sensitivity of 75% and specificity of 89.6% in experienced hands(39). More robust alternatives are 
therefore CT angiography and gadolinium-enhanced MR angiography (MRA). CT angiography has 
excellent spatial and temporal resolution with a sensitivity of 94% and specificity of 93% for 
detecting RAS(39), however, CT angiography exposes patients to ionizing radiation and requires the 
use of an iodinated contrast agent, with a risk of contrast induced nephropathy in patients with 
renal impairment(40). Gadolinium-enhanced MRA, as used in this study, has now become much 
more widely available and has a similar sensitivity and specificity to CT angiography (90% and 94.1% 
respectively), although does carry a very small risk of NSF in patients with renal impairment as 
described above.  
Adrenal masses and hyperplasia can be detected using MRI, however the frequent occurrence of 
incidental adrenal masses, commonly non-active adenomas, means that biochemical assessment 
should be the primary screening tool for endocrine hypertension(31). Our MRI protocol includes a 
simple single breath-hold axial T1-weighted imaging stack (5mm slice thickness) through the 
abdomen to screen for ‘resolvable’ adrenal lesions and so small abnormalities may be missed. High 
resolution adrenal CT or MRI, beyond our study protocol, is therefore required in patients with 
positive biochemistry to identify microadenomas and differentiate between phaeochromocytomas 
and adenomas presenting as Conn’s or Cushing’s syndrome(6, 31). Pituitary lesions can be seen on 
standard MRI, however, a dedicated, contrast-enhanced MRI scan is also required to localize 
pituitary microadenomas(6).  
In this study only 2/12 adrenal masses were hormonally active and only 2/10 cases of renal artery 
stenoses went on to be stented. Furthermore, following initial investigation with MRI further 
imaging was recommended in 12% of patients (see Table 3). Did these other findings and 
investigations generate unnecessary patient stress or healthcare costs?  
Incidental findings may be identified via any imaging modality, however it is more likely when 
performing cross-sectional imaging of large areas of the body as seen with MRI and CT. The patients 
in this study were already undergoing assessment for secondary hypertension with concurrent 
endocrine testing, we were therefore able to interpret any adrenal abnormalities in the context of 
the patient’s endocrine profile, and so in clinical practice we have found these investigations to be 
complimentary. On the other hand, patients with ‘normal’ adrenals on MRI but a positive endocrine 
diagnosis would in practice require additional, high resolution focused adrenal imaging.  
RAS is a recognised cause of hypertension(38), however the management of RAS has become 
controversial following data from studies, including the ASTRAL and CORAL trials, which showed no 
benefit of renal artery stenting over medical management with renin-angiotensin system 
blockade(41, 42). The picture has been further complicated by the advent of renal denervation; 
assessment of renal artery anatomy is used to screen for suitability for this interventional treatment 
for hypertension(43, 44).  
Finally, other incidental findings may have both positive and negative impacts on patients. For 
example, the novel finding of a bicuspid aorta valve means that patients can be put under 
surveillance for significant valvular dysfunction or aortopathy, and whilst this may well create 
additional anxiety, early identification of these issues may prevent serious complications. In light of 
these concerns, we would emphasise that MRI is best targeted at those patients in which the 
increased likelihood of target organ or secondary causes of hypertension can justify the impact of 
any incidental findings. 
Limitations 
This study is a retrospective analysis of prospectively gathered clinical MRI data; as such we have no 
control group, and therefore cannot comment on the prevalence of target organ damage or 
secondary hypertension found on imaging in comparison with a normotensive population. 
Additionally, we are unable to present a comparison between our MRI data and baseline data 
acquired using more conventional investigation techniques across our full cohort, and where 
comparisons were made with other imaging modalities, the data was in the form of non-
standardised clinical reports. There was also a proportion of patients seen in the hypertension clinic 
in which MRIwas not indicated (especially if previously investigated), and patients who were not 
referred for MRI due to a history of claustrophobia, metal foreign body or implant, or morbid obesity 
meaning that their girth was too large for the MRI scanner; this may represent a selection bias. We 
clearly recognise that this is a skewed population of hypertensive patients who have been referred 
for further assessment in a specialist clinic, and these data cannot be extrapolated to the general 
hypertensive population who are routinely managed in primary care.  
Finally,  the cost of MRI and access to this imaging modality can be extremely variable. We 
acknowledge that no formal cost-benefit analysis has been performed for MRI assessment versus 
echocardiography and renal ultrasound/CT in this cohort (the approximate costs of these different 
investigations are shown in Supplementary Table 2). Existing data indicates that there may be a cost-
benefit of echocardiography over ECG in the diagnosis of LVH in selected populations, but there is 
little formal data on any potential cost-benefit of MRI vs standard techniques and further research is 
required(45, 46).  
Conclusions 
MRI is a safe and effective imaging modality for screening patients with high blood pressure for 
asymptomatic target organ damage and secondary causes of hypertension. It provides high 
diagnostic specificity and sensitivity for identifying left ventricular hypertrophy and renal artery 
stenosis, and whilst CMR is not one of the primary imaging modalities recommended in clinical 
hypertension guidelines(2), it is the current gold standard for the non-invasive assessment of left 
ventricular volumes, mass and function(6, 31). We acknowledge that MRI remains a relatively 
expensive investigation and is not routinely available in the community, however diagnostic 
information from multiple organ systems can be obtained from a one hour scanning session, and this 
increased efficiency will be of benefit to patients. Target organ damage was identified in >75% of our 
study population, resulting in the initiation of secondary prevention medication in those with newly 
identified cardiovascular disease, and triggering the initiation of anti-hypertensive medication in 
many of those with young onset hypertension. Given the high prevalence of target organ damage 
reported in this study and the clinical impact of our findings, we recommend that MRI should be 
used as the primary imaging modality in tertiary hypertension clinics. 
 
Acknowledgments  
This work was supported by the NIHR Bristol Cardiovascular Biomedical Research Unit, Bristol Heart 
Institute. The views expressed are those of the authors and not necessarily those of the National 
Health Service, National Institute for Health Research, or Department of Health. AEB is funded by a 
University Hospitals Bristol NHS Foundation Trust Clinical Research Fellowship. JCLR is funded by 
Clinical Society of Bath Postgraduate Research Bursary 2014 and Royal College of Radiologists Kodak 
Research Scholarship 2014. ECH and JFRP are funded by the British Heart Foundation.   
References  
1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. 
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC 
guidelines for the management of arterial hypertension: the Task Force for the Management of 
Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of 
Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. 
3. National Clinical Guideline CG127. Hypertension in adults: diagnosis and management. 
National Institute for Health and Clinical Excellence. 2011. https://www.nice.org.uk/guidance/cg127. 
4. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular 
magnetic resonance. Hypertension. 2002;39(3):750-5. 
5. Maceira AM, Prasad SK, Pennell DJ, Mohiaddin RH. Integrated evaluation of hypertensive 
patients with cardiovascular magnetic resonance. Int J Cardiol. 2008;125(3):383-90. 
6. Roditi G. MR in hypertension. J Magn Reson Imaging. 2011;34(5):989-1006. 
7. National Clinical Guideline CG189. Obesity: identification, assessment and management. 
National Institute for Health and Clinical Excellence. 2014.  
https://www.nice.org.uk/guidance/cg189. 
8. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular 
magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461-
74. 
9. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic 
function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn 
Reson. 2006;8(3):417-26. 
10. Childs H, Ma L, Ma M, Clarke J, Cocker M, Green J, et al. Comparison of long and short axis 
quantification of left ventricular volume parameters by cardiovascular magnetic resonance, with ex-
vivo validation. J Cardiovasc Magn Reson. 2011;13:40. 
11. Hudsmith† L, Petersen† S, Francis J, Robson M, Neubauer S. Normal Human Left and Right 
Ventricular and Left Atrial Dimensions Using Steady State Free Precession Magnetic Resonance 
Imaging. J Cardiovasc Magn Reson. 2005;7(5):775-82. 
12. Buchner S, Debl K, Haimerl J, Djavidani B, Poschenrieder F, Feuerbach S, et al. 
Electrocardiographic diagnosis of left ventricular hypertrophy in aortic valve disease: evaluation of 
ECG criteria by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11:18. 
13. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC 
Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the 
Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology 
(ESC). Eur Heart J. 2014;35(39):2733-79. 
14. Rodrigues JC, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe LE, et al. 
Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular 
magnetic resonance discriminators when end-diastolic wall thickness >/= 15 mm. Eur Radiol. 2016. 
15. Rodrigues JC, Amadu AM, Dastidar AG, Szantho GV, Lyen SM, Godsave C, et al. 
Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. Heart. 
2016. 
16. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy 
in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343-
9. 
17. Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant hypertension and left ventricular 
hypertrophy: an overview. J Am Soc Hypertens. 2010;4(6):319-24. 
18. Rudnick KV, Sackett DL, Hirst S, Holmes C. Hypertension in a family practice. Can Med Assoc 
J. 1977;117(5):492-7. 
19. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence 
of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. 
Hypertens Res. 2004;27(3):193-202. 
20. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: 
studies in a random population sample. BMJ. 1976;2(6035):554-6. 
21. Štrauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J. Prevalence of primary 
hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum 
Hypertens. 2003;17(5):349-52. 
22. Limonta LBS, Valandro Ldos S, Shiraishi FG, Barretti P, Franco RS, Martin LC. Causes of 
Resistant Hypertension Detected by a Standardized Algorithm. Int J Hypertens. 2012;2012. 
23. Bacharova L, Chen H, Estes EH, Mateasik A, Bluemke DA, Lima JAC, et al. Determinants of 
Discrepancies in Detection and Comparison of the Prognostic Significance of Left Ventricular 
Hypertrophy by Electrocardiogram and Cardiac Magnetic Resonance Imaging. Am J Cardiol. 
2015;115(4):515-22. 
24. Rodrigues JC, McIntyre B, Dastidar AG, Lyen SM, Ratcliffe LE, Burchell AE, et al. The effect of 
obesity on electrocardiographic detection of hypertensive left ventricular hypertrophy: recalibration 
against cardiac magnetic resonance. J Hum Hypertens. 2016;30(3):197-203. 
25. Myerson SG, Montgomery HE, World MJ, Pennell DJ. Left ventricular mass: reliability of M-
mode and 2-dimensional echocardiographic formulas. Hypertension. 2002;40(5):673-8. 
26. Germain P, Roul G, Kastler B, Mossard JM, Bareiss P, Sacrez A. Inter-study variability in left 
ventricular mass measurement. Comparison between M-mode echography and MRI. Eur Heart J. 
1992;13(8):1011-9. 
27. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance 
imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. 
Am J Hypertens. 1995;8(3):221-8. 
28. Rodrigues JC, Rohan S, Dastidar AG, Trickey A, Szantho G, Ratcliffe LE, et al. The Relationship 
Between Left Ventricular Wall Thickness, Myocardial Shortening, and Ejection Fraction in 
Hypertensive Heart Disease: Insights From Cardiac Magnetic Resonance Imaging. J Clin Hypertens. 
2016. 
29. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular 
concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive 
patients. Hypertension. 2004;43(4):731-8. 
30. Ishida M, Kato S, Sakuma H. Cardiac MRI in ischemic heart disease. Circ J. 2009;73(9):1577-
88. 
31. Maceira AM, Mohiaddin RH. Cardiovascular magnetic resonance in systemic hypertension. J 
Cardiovasc Magn Reson. 2012;14:28. 
32. Rodrigues JC, Amadu AM, Dastidar AG, Hassan N, Lyen SM, Lawton CB, et al. Prevalence and 
predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with 
cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2015. 
33. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of 
nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248(3):807-16. 
34. European Medicines Agency - Human medicines - Gadolinium-containing contrast agents 
2016. Available from: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-
containing_contrast_agents/human_referral_000182.jsp&mid=WC0b01ac05805c516f. 
35. Kuruvilla S, Janardhanan R, Antkowiak P, Keeley EC, Adenaw N, Brooks J, et al. Increased 
extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, 
not hypertension alone. JACC Cardiovasc Imaging. 2015;8(2):172-80. 
36. Rodrigues JC, Amadu AM, Ghosh Dastidar A, McIntyre B, Szantho GV, Lyen S, et al. ECG strain 
pattern in hypertension is associated with myocardial cellular expansion and diffuse interstitial 
fibrosis: a multi-parametric cardiac magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2016. 
37. Biglino G, Steeden JA, Baker C, Schievano S, Taylor AM, Parker KH, et al. A non-invasive 
clinical application of wave intensity analysis based on ultrahigh temporal resolution phase-contrast 
cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:57. 
38. Benjamin MM, Fazel P, Filardo G, Choi JW, Stoler RC. Prevalence of and risk factors of renal 
artery stenosis in patients with resistant hypertension. Am J Cardiol. 2014;113(4):687-90. 
39. Sarkodieh JE, Walden SH, Low D. Imaging and management of atherosclerotic renal artery 
stenosis. Clin Radiol. 2013;68(6):627-35. 
40. Lufft V, Hoogestraat-Lufft L, Fels LM, Egbeyong-Baiyee D, Tusch G, Galanski M, et al. Contrast 
media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography 
in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis. 2002;40(2):236-42. 
41. Tuttle KR, Dworkin LD, Henrich W, Greco BA, Steffes M, Tobe S, et al. Effects of Stenting for 
Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. 
Clin J Am Soc Nephrol. 2016. 
42. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization versus 
medical therapy for renal-artery stenosis. New Engl J Med. 2009;361(20):1953-62. 
43. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic 
denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a 
randomised controlled trial. Lancet. 2010;376(9756):1903-9. 
44. Burchell AE, Chan K, Ratcliffe LE, Hart EC, Saxena M, Collier DJ, et al. Controversies 
Surrounding Renal Denervation: Lessons Learned From Real-World Experience in Two United 
Kingdom Centers. J Clin Hypertens. 2016;18(6):585-92. 
45. Leese PJ, Viera AJ, Hinderliter AL, Stearns SC. Cost-effectiveness of electrocardiography vs. 
electrocardiography plus limited echocardiography to diagnose LVH in young, newly identified, 
hypertensives. Am J Hypertens. 2010;23(6):592-8. 
46. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Zanchetti A. Left ventricular hypertrophy and 
cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently 
diagnosed essential hypertensives. J Hypertens. 2006;24(8):1671-7. 
47. Schimmenti LA. Renal coloboma syndrome. Eur J Hum Genet. 2011;19(12):1207-12. 
48. Zubair AS, Salameh H, Erickson SB, Prieto M. Loin pain hematuria syndrome. Clin Kidney J. 
2016;9(1):128-34. 
49. Gambaro G, Fulignati P, Spinelli A, Rovella V, Di Daniele N. Percutaneous renal sympathetic 
nerve ablation for loin pain haematuria syndrome. Nephrol Dial Transplant. 2013;28(9):2393-5. 
50. Greenwell TJ, Peters JL, Neild GH, Shah PJ. The outcome of renal denervation for managing 
loin pain haematuria syndrome. BJU international. 2004;93(6):818-21. 
51. Cuspidi C, Facchetti R, Bombelli M, Sala C, Grassi G, Mancia G. Accuracy and prognostic 
significance of electrocardiographic markers of left ventricular hypertrophy in a general population: 
findings from the Pressioni Arteriose Monitorate E Loro Associazioni population. J Hypertens. 
2014;32(4):921-8. 
52. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of 
echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J 
Med. 1990;322(22):1561-6. 
53. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left 
ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential 
hypertension. Circulation. 2001;104(17):2039-44. 
54. Nosir YF, Lequin MH, Kasprzak JD, van Domburg RT, Vletter WB, Yao J, et al. Measurements 
and day-to-day variabilities of left ventricular volumes and ejection fraction by three-dimensional 
echocardiography and comparison with magnetic resonance imaging. Am J Cardiol. 1998;82(2):209-
14. 
55. Kuhl HP, Bucker A, Franke A, Maul S, Nolte-Ernsting C, Reineke T, et al. Transesophageal 3-
dimensional echocardiography: in vivo determination of left ventricular mass in comparison with 
magnetic resonance imaging. J Am Soc Echo. 2000;13(3):205-15. 
56. Mousseaux E, Beygui F, Fornes P, Chatellier G, Hagege A, Desnos M, et al. Determination of 
left ventricular mass with electron beam computed tomography in deformed, hypertrophic human 
hearts. Eur Heart J. 1994;15(6):832-41. 
57. Klein R, Ametepe ES, Yam Y, Dwivedi G, Chow BJ. Cardiac CT assessment of left ventricular 
mass in mid-diastasis and its prognostic value. Eur Heart J. 2016. 
58. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for 
studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc 
Magn Reson. 2000;2(4):271-8. 
59. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of 
interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional 
echocardiography in normal subjects and in patients with heart failure or left ventricular 
hypertrophy. Am J Cardiol. 2002;90(1):29-34. 
60. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, et al. Left 
ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic 
performance. Hypertension. 2010;56(1):91-8. 
 
  
Figure Legends  
 
Figure 1. MRI of target organ damage in hypertension. A. Left ventricular mid-cavity steady state 
free precession (SSFP) short-axis cine image at end-diastole (Ai) left-ventricular 4-chamber / 
horizontal long-axis SSFP cine image at end-diastole (Aii) images from the same patient showing 
elevated indexed left ventricular mass consistent with left ventricular hypertrophy. B. Left 
ventricular mid-cavity SSFP cine image at end-diastole from another patient demonstrating left 
ventricular hypertrophy (Bi) LV short-axis mid-cavity magnitude inversion recovery myocardial late 
gadolinium enhancement image showing evidence of patchy mid-wall replacement myocardial 
fibrosis (Bii, indicated by arrow) – these findings raises the possibility of previously undiagnosed 
hypertrophic cardiomyopathy in this case. C&D. Phase Sensitive Inversion Recovery (PSIR) images 
showing late gadolinium enhancement of (C) a lateral, subendocardial infarction and (D) an infero-
lateral (circumflex territory), subendocardial infarction (indicated by arrows). 
 
 
Figure 2. Secondary causes of hypertension demonstrated on MRI. A. Maximal intensity, arterial 
phase, coronal image (TWIST-MR angiography) showing left ostial renal artery stenosis (indicated by 
arrow) with left accessory renal artery inferior to main renal artery. B. TWIST-MRA showing right 
accessory renal artery (incidental finding, indicated by arrow). C. Single left mal-rotated and 
inferiorly positioned kidney in a patient with renal coloboma syndrome (delayed phase coronal 
image from TWIST-MRA showing arterial and venous phase imaging). D. Multiple hypo-attenuating, 
well-defined entities in both renal cortices on nephrographic phase imaging from coronal TWIST-
MRA, which represent renal cysts in a patient with polycystic kidney disease (see arrows). E. 
Maximum intensity projection sagittal image showing coarctation of the aorta just distal to the left 
subclavian artery (marked by arrow) and numerous collateral vessels (starred). F. Right benign 
adrenal nodule (see arrow). G. Bilateral adrenal phaeochromocytomas in a patient with multiple 
endocrine neoplasia type IIa (see arrows). H. Large left thyroid nodule (see arrow). F, G and H are 
axial HASTE images. 
 
  
Tables  
Parameter All 
Patients 
(n=200) 
Patient Hypertension Subgroups 
Drug 
Resistant 
(n=76) 
Young 
Onset 
(n=64) 
Uncontrolled 
(n=35) 
Other* 
(n=25) 
Age (years) 51 ± 15 58 ± 10 35 ± 9 65 ± 9 53 ± 10 
Gender (no. male) 115 (56%) 46 (61%) 37 (58%) 17 (49%) 15 (60%) 
BMI (kg/m2) 30 ± 6 31 ± 5 29 ± 7 29 ± 5 31 ± 6 
No. anti-
hypertensives 
3.1 ± 2.0 4.8 ± 1.5 1.9 ± 1.5 2.0 ± 1.3 2.2 ± 1.3 
SBP (mmHg) 168 ± 30 178 ± 29 152 ± 22 187 ± 27 154 ± 23 
DBP (mmHg) 96 ± 16 99 ± 17 94 ± 11 100 ± 16 91 ± 16 
LVM (g/m2) 87 ± 28 96 ± 31 78 ± 24 83 ± 21 87 ± 29 
Table 1. Patient demographics, by hypertension subgroup. BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; LVM, left ventricular mass indexed to body surface 
area. *Includes patients with accelerated hypertension, highly labile hypertension, or hypertension 
with disproportionate target organ damage warranting further investigation. 
  
 Parameter All Patients 
(n=200) 
Patient Hypertension Subgroups 
Drug 
Resistant 
(n=76) 
Young 
Onset 
(n=64) 
Uncontrolled 
(n=35) 
Other* 
(n=25) 
P value 
Target organ 
damage, n (%) 
157 (79) 70 (92) 38 (59) 31 (89) 18 (72) <0.0001 
Left ventricular 
hypertrophy, n (%) 
122 (61) 56 (74) 24 (38) 26 (74) 16 (64) <0.0001 
Secondary causes, 
n (%) 
29 (15) 13 (17) 4 (6) 8 (23) 7 (28) =0.04 
Table 2. Prevelence of all types of target organ damage, left ventricular hypertrophy and potential 
secondary causes of hypertension identified on MRI, with comparison by hypertensive subgroups. 
*Includes patients with accelerated hypertension, highly labile hypertension, or hypertension with 
disproportionate target organ damage warranting further investigation.  
  
Pathology No. 
cases 
Details 
Adrenal mass 12  7 lesions were not hormonally active. 
- 1 reported as a likely phaemochromocytoma 
on MRI, but non-functional adenoma 
following endocrine testing and dedicated 
adrenal CT.  
 1 patient with bilateral phaeochromocytomas and a 
thyroid nodule diagnosed with multiple endocrine 
neoplasia type 2a, now under oncological treatment. 
 1 patient had a resolution of their hypertension 
following treatment with spironolactone.  
 3 patients have not had endocrine pathology 
excluded 
- 1 died of a stroke prior to investigation 
- 1 emigrated prior to full investigation 
- 1 is still under investigation  
 Renal artery 
stenosis 
10 Cases reviewed at renal multidisciplinary team meeting:  
 2 referred for stenting 
 8 for medical management 
Renal abnormality 21 6/21 findings may reflect secondary hypertension: 
 2 atrophy secondary to RAS 
 2 atrophy not related to RAS 
 1 polycystic kidney disease; consistent with family 
history of the condition.  
 1 single hypoplastic, malrotated kidney in keeping 
with previous diagnosis of renal coloboma syndrome 
(autosomal dominant condition characterised by 
renal hypodysplasia, optic nerve dysplasia and 
hypertension)(47) 
15/21 findings likely incidental: 
 9 uni- or bilateral simple cyst(s)  
 4 anatomical variants not felt to cause hypertension 
(e.g. horseshoe kidney and duplex malrotated 
kidney) 
 1 patient with pelvicalyceal dilatation and possible 
renal parenchymal abnormality; further defined on 
CT and felt to be benign. 
 1 previous nephrectomy for loin pain haematuria 
syndrome. 
- Not known to cause hypertension(48); 
referral for renal denervation to treat 
concurrent resistant hypertension and, 
potentially, loin pain(49, 50). 
Thyroid 
abnormality 
7 Goitre and nodules; assessed biochemically and 
referred further investigation if indicated. 1 case MEN2a 
see above. 
Pituitary 
enlargement 
1 Investigated with pituitary function testing and a 
pituitary MRI; non-functional. 
Aortic coarctation 1 Associated with bicuspid aortic valve and aortopathy. 
 Novel diagnosis, hypertension resolved following 
endovascular stenting. 
Incidental findings  3 bicuspid aorta valves (now on surveillance), 1 
pulmonary nodule, 2 splenomegaly, 1 liver lesion 
(haemangioma), gallstones, uterine fibroids, and breast, 
liver, pancreatic and renal cysts. 
Table 3. Secondary causes of hypertension, and other incidental findings, as demonstrated by MRI. 
RAS, renal artery stenosis. 
  
 Investigation Benefits Limitations Supporting references 
Electrocardiogram • Safe, cheap and 
accessible. 
• Prognostic data. 
• Low sensitivity for LVH, 
especially in obesity. 
Cuspidi et al. 2014(51) 
Bacharova et al. 
2015(23) 
Rodrigues et al. 
2016(24) 
2D Echocardiography • Safe, low cost and 
widely available. 
• Good sensitivity for LVH 
and significant 
myocardial infarction. 
• Prognostic data. 
• Images can be limited 
by body habitus. 
• Geometrical 
assumptions made for 
the quantification of LV 
volumes. 
Levy et al. 1990(52) 
Verdecchia et al. 
2001(53) 
Myerson et al. 
2002(25) 
3D Echocardiography • Safe. 
• Similar accuracy for 
estimation of LVM to 
CMR. 
• Specialist equipment 
and trained operators 
required with limited 
availability. 
Nosir et al. 1998(54) 
Kuhl et al. 2000(55) 
Cardiac CT • Multiple images slices 
attained in a single 
breath hold. 
• Reasonable accuracy. 
• Prognostic data. 
• Exposure to ionizing 
radiation and requires 
intravenous contrast 
agent. 
Mousseaux et al. 
1994(56) 
Klein et al. 2016(57) 
 
CMR • Safe, non-ionising. 
• Superior accuracy and 
reproducibility for the 
quantification of LVM 
compared with 2D 
echocardiography.  
• Late gadolinium 
enhancement assesses 
fibrosis/scar. 
• Helpful to define 
aetiology of LVH. 
• Prognostic data. 
• Can reduce sample size 
in research studies. 
• Limited accessibility 
outside specialist 
centres, high cost. 
• Contraindicated for 
device implants, 
cerebral clips, 
claustrophobia, etc.  
• Possible incidental 
findings. 
• Risk of nephrogenic 
sclerosing fibrosis in 
patients with significant 
renal impairment. 
Bottini et al. 1995(27) 
Bellenger et al. 
2000(58) 
Grothues et al. 
2002(59) 
Myerson et al. 2002(4) 
Chirinos et al. 
2010(60) 
 
Table 4. Comparison between different investigation modalities for the evaluation of left 
ventricular hypertrophy. CT, computerised tomography; CMR, cardiac magnetic resonance; LVH, left 
ventricular hypertrophy; LVM, left ventricular mass. 
AiiAi
DBiiBi
C
A. E.D.C.B.
H.G.F.
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Imaging modality Cohort size 
(n=) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
References 
Electrocardiogram 
- Sokolow–Lyon voltage 
 
128 
 
19 
 
93 
 
60 
 
66 
 
Rodrigues et al. 2016,  
  Hypertensives(1) 
- Sokolow–Lyon product 128 17 96 72 66 Rodrigues et al. 2016,  
  Hypertensives(1) 
- Cornell voltage 
 
128 43 84 61 72 Rodrigues et al. 2016,  
  Hypertensives(1) 
- Sokolow–Lyon and/or 
Cornell voltage 
 
4748 16 95 35 87 Bacharova et al. 2015,  
  Multi-ethnic study of  
  atherosclerosis(2) 
- Sokolow–Lyon voltage 
 
228 29 92 - - Alfakih et al, 2004, 
  Hypertensives(3) 
- Sokolow–Lyon product 228 37 91 - - Alfakih et al, 2004, 
  Hypertensives(3) 
- Cornell voltage 
 
228 21 95 - - Alfakih et al, 2004, 
  Hypertensives(3) 
- Cornell product 
 
228 31 91 - - Alfakih et al, 2004, 
  Hypertensives(3) 
2D Echocardiography 84 79 68 77 70 This study cohort, 2016 
  Hypertensives 
 80 86 85 55 97 Jackubovic et al, 2013 
  Dialysis/controls(4) 
Supplementary Table 1: Examples of sensitivities, specificities and predictive values for the 
diagnosis of left ventricular hypertrophy by different techniques versus cardiac magnetic resonnce 
(CMR). PPV, positive predictive value; NPV, negative predictive value. 
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 Imaging Modality Cost, USD (GBP) 
Echocardiogram $ 120   (£80) 
Renal ultrasound $ 75   (£50) 
CT angiogram – renal $ 135   (£90) 
Complex CT – e.g. adrenal imaging $ 670   (£450) 
Hypertension MRI $ 600   (£400) 
Supplementary Table 2: Costs for different imaging modalities. These prices represent the current 
cost of these investigations at our Institution and are given for reference, however prices will show 
considerable geographical variation. Conversion from Great British Pounds (GBP) to United States 
Dollars (USD) correct June 2016.  
 
 
 
 
